Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186469 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL4945 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL867090 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL5176 | 1.00 | — | — | |
| SCHEMBL21831592 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL867442 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL9259493 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL21831419 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL22027477 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL4941 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4345092-A1 | NITROBENZAMIDE COMPOUNDS, METHODS AND USES THEREOF | Faculdade de Farmácia da Universidade de Lisboa (PT) | 2024-04-03 | — | — | EP | disclosed |
| EP-4345091-A1 | BENZOIC ACID DERIVATIVES, METHODS AND USES THEREOF | Faculdade de Farmácia da Universidade de Lisboa (PT) | 2024-04-03 | — | — | EP | disclosed |
| US-20240092793-A1 | CHROMENE-BASED COMPOUNDS, METHODS AND USES THEREOF | University of Minho (PT) | 2024-03-21 | — | — | US | disclosed |
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | QUADREL S.R.L. (IT) | 2023-11-16 | — | — | US | disclosed |
| EP-4216960-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | Quadrel S.r.l. (IT) | 2023-08-02 | — | — | EP | disclosed |
| CN-109843896-B | Hydroxycinnamic acid derivatives, methods and uses thereof | 波尔图大学 | 2022-12-20 | — | — | CN | disclosed |
| CN-110114365-B | Hydroxybenzoic acid derivatives, process and use thereof | 波尔图大学 | 2022-12-13 | — | — | CN | disclosed |
| EP-3990118-A1 | CHROMENE-BASED COMPOUNDS, METHODS AND USES THEREOF | Universidade do Minho (PT) | 2022-05-04 | — | — | EP | disclosed |
| CN-114026098-A | Benzopyran based compounds, methods and uses thereof | 米尼翁大学 | 2022-02-08 | — | — | CN | disclosed |
| WO-2021191882-A1 | ANTIMALARIAL AGENT, METHODS AND USES THEREOF | UNIVERSIDADE DO MINHO (PT) | 2021-09-30 | — | — | WO | disclosed |
| US-5428033-A | Useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotecyive agents | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| US-5266568-A | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-11-30 | — | — | US | disclosed |
| US-5221678-A | Cardiovascular disorders, antiinflammatory agents, antiallergens | MERCK FROSST CANADA, INC. (CA) | 1993-06-22 | — | — | US | disclosed |
| US-5187180-A | Asthma; eye inflamation | MERCK FROSST CANADA, INC. (CA) | 1993-02-16 | — | — | US | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480716-A1 | Saturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480708-A2 | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0468785-A2 | (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1992-01-29 | — | — | EP | disclosed |
| EP-0468789-A2 | (Quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | PIGO, PIGS, AGPS | CHRM5 1894/4885CYP1A2 1194/4885ADRA2C 3543/4885 |
| US-20240092793-A1 | CHROMENE-BASED COMPOUNDS, METHODS AND USES THEREOF | CYP3A43, CTRB2, CHRM3 | CHRM5 29/4885CYP1A2 26/4885ADRA2C 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.